APO Research
Talk to an analyst

APO RESEARCH · REPORT

Vasodilators for Heart Disease

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Vasodilators for Heart Disease Market Outlook and Growth Opportunities 2026

27 December 2025216 pages

Choose your research edition.

Industry ResearchVasodilators for Heart Disease Industry Research Report 2026149 pages · $2,950 USDIndustry Growth & TrendsGlobal Vasodilators for Heart Disease Industry Growth and Trends Forecast to 2032123 pages · $3,450 USDMarket StructureGlobal Vasodilators for Heart Disease Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032194 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Vasodilators for Heart Disease Market Outlook and Growth Opportunities 2026216 pages · $4,250 USDMarket Analysis & ForecastGlobal Vasodilators for Heart Disease Market Analysis and Forecast 2026-2032216 pages · $4,950 USD

Market perspective

The global Vasodilators for Heart Disease market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Vasodilators for Heart Disease is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Vasodilators for Heart Disease is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Vasodilators for Heart Disease is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Vasodilators for Heart Disease market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Vasodilators for Heart Disease market include Chongqing Yaoyou Pharmaceutical Co., Ltd., Southwest Pharmaceutical Co., Ltd., Shanghai Hefeng Pharmaceutical Co., Ltd., Shanghai Aifa Pharmaceutical Co., Ltd., Shanxi Kangbao Biological Products Co., Ltd., Shandong New Era Pharmaceutical Co., Ltd., Shandong Fangming Pharmaceutical Group Co., Ltd., Sancai Shiqi Pharmaceutical Co., Ltd. and Lunan Beite Pharmaceutical Co., Ltd., among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Vasodilators for Heart Disease market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Vasodilators for Heart Disease and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Vasodilators for Heart Disease sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Vasodilators for Heart Disease market size, projected growth trends, production technologies, key applications, and end-use industries.

Vasodilators for Heart Disease Segment by Company

Chongqing Yaoyou Pharmaceutical Co., Ltd.

Southwest Pharmaceutical Co., Ltd.

Shanghai Hefeng Pharmaceutical Co., Ltd.

Shanghai Aifa Pharmaceutical Co., Ltd.

Shanxi Kangbao Biological Products Co., Ltd.

Shandong New Era Pharmaceutical Co., Ltd.

Shandong Fangming Pharmaceutical Group Co., Ltd.

Sancai Shiqi Pharmaceutical Co., Ltd.

Lunan Beite Pharmaceutical Co., Ltd.

Jiangxi Haiersi Pharmaceutical Co., Ltd.

Jiangsu Tasly Diyi Pharmaceutical Co., Ltd.

Jiangsu Shenlong Pharmaceutical Co., Ltd.

Jiangsu Jiuxu Pharmaceutical Co., Ltd.

Huiyinbi Group Jiangxi East Asia Pharmaceutical Co., Ltd.

Hulunbeier Songlu Pharmaceutical Co., Ltd.

Henan Runhong Pharmaceutical Co., Ltd.

Guangzhou Baiyunshan Mingxing Pharmaceutical Co., Ltd.

Chenxin Pharmaceutical Co., Ltd.

Beijing Yimin Pharmaceutical Co., Ltd.

Beijing Hengsheng Pharmaceutical Co., Ltd.

Anhui Fengyuan Pharmaceutical Co., Ltd.

TORRENT PHARMA INC.

Sanofi

Pfizer

Matins Pharma

Copperhead Chemical Company

Axplora

Aditya Chemicals

Vasodilators for Heart Disease Segment by Type

Isosorbide Mononitrate

Nicorandil

Nitroglycerin

Isosorbide Dinitrate

Vasodilators for Heart Disease Segment by Application

Clinic

Hospital

Other

Vasodilators for Heart Disease Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Vasodilators for Heart Disease status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Vasodilators for Heart Disease market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Vasodilators for Heart Disease significant trends, drivers, influence factors in global and regions.

6. To analyze Vasodilators for Heart Disease competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Vasodilators for Heart Disease market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Vasodilators for Heart Disease and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Vasodilators for Heart Disease.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Vasodilators for Heart Disease market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Vasodilators for Heart Disease industry.

Chapter 3: Detailed analysis of Vasodilators for Heart Disease manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Vasodilators for Heart Disease in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Vasodilators for Heart Disease in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Vasodilators for Heart Disease Industry Trends Table 2. Vasodilators for Heart Disease Industry Drivers Table 3. Vasodilators for Heart Disease Industry Opportunities and Challenges Table 4. Vasodilators for Heart Disease Industry Restraints Table 5. Global Vasodilators for Heart Disease Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Vasodilators for Heart Disease Revenue Share by Company (2021-2026) Table 7. Global Vasodilators for Heart Disease Sales Volume by Company (Units) & (2021-2026) Table 8. Global Vasodilators for Heart Disease Sales Volume Share by Company (2021-2026) Table 9. Global Vasodilators for Heart Disease Average Price (US$/Unit) of Company (2021-2026) Table 10. Global Vasodilators for Heart Disease Company Ranking, (2024-2026) & (USD Million) Table 11. Global Vasodilators for Heart Disease Key Company Manufacturing Base & Headquarters Table 12. Global Vasodilators for Heart Disease Company, Product Type & Application Table 13. Global Vasodilators for Heart Disease Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Vasodilators for Heart Disease by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Isosorbide Mononitrate Table 18. Significant Companies of Nicorandil Table 19. Significant Companies of Nitroglycerin Table 20. Significant Companies of Isosorbide Dinitrate Table 21. Global Vasodilators for Heart Disease Sales Volume by Type 2021 VS 2025 VS 2032 (Units) Table 22. Global Vasodilators for Heart Disease Sales Volume by Type (2021-2026) & (Units) Table 23. Global Vasodilators for Heart Disease Sales Volume by Type (2027-2032) & (Units) Table 24. Global Vasodilators for Heart Disease Sales Volume Share by Type (2021-2026) Table 25. Global Vasodilators for Heart Disease Sales Volume Share by Type (2027-2032) Table 26. Global Vasodilators for Heart Disease Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 27. Global Vasodilators for Heart Disease Sales Value by Type (2021-2026) & (US$ Million) Table 28. Global Vasodilators for Heart Disease Sales Value by Type (2027-2032) & (US$ Million) Table 29. Global Vasodilators for Heart Disease Sales Value Share by Type (2021-2026) Table 30. Global Vasodilators for Heart Disease Sales Value Share by Type (2027-2032) Table 31. Significant Companies of Clinic Table 32. Significant Companies of Hospital Table 33. Significant Companies of Other Table 34. Global Vasodilators for Heart Disease Sales Volume by Application 2021 VS 2025 VS 2032 (Units) Table 35. Global Vasodilators for Heart Disease Sales Volume by Application (2021-2026) & (Units) Table 36. Global Vasodilators for Heart Disease Sales Volume by Application (2027-2032) & (Units) Table 37. Global Vasodilators for Heart Disease Sales Volume Share by Application (2021-2026) Table 38. Global Vasodilators for Heart Disease Sales Volume Share by Application (2027-2032) Table 39. Global Vasodilators for Heart Disease Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 40. Global Vasodilators for Heart Disease Sales Value by Application (2021-2026) & (US$ Million) Table 41. Global Vasodilators for Heart Disease Sales Value by Application (2027-2032) & (US$ Million) Table 42. Global Vasodilators for Heart Disease Sales Value Share by Application (2021-2026) Table 43. Global Vasodilators for Heart Disease Sales Value Share by Application (2027-2032) Table 44. Global Vasodilators for Heart Disease Sales by Region: 2021 VS 2025 VS 2032 (Units) Table 45. Global Vasodilators for Heart Disease Sales by Region (2021-2026) & (Units) Table 46. Global Vasodilators for Heart Disease Sales Market Share by Region (2021-2026) Table 47. Global Vasodilators for Heart Disease Sales by Region (2027-2032) & (Units) Table 48. Global Vasodilators for Heart Disease Sales Market Share by Region (2027-2032) Table 49. Global Vasodilators for Heart Disease Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 50. Global Vasodilators for Heart Disease Sales Value by Region (2021-2026) & (US$ Million) Table 51. Global Vasodilators for Heart Disease Sales Value Share by Region (2021-2026) Table 52. Global Vasodilators for Heart Disease Sales Value by Region (2027-2032) & (US$ Million) Table 53. Global Vasodilators for Heart Disease Sales Value Share by Region (2027-2032) Table 54. Global Vasodilators for Heart Disease Market Average Price (US$/Unit) by Region (2021-2026) Table 55. Global Vasodilators for Heart Disease Market Average Price (US$/Unit) by Region (2027-2032) Table 56. Global Vasodilators for Heart Disease Sales by Country: 2021 VS 2025 VS 2032 (Units) Table 57. Global Vasodilators for Heart Disease Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 58. Global Vasodilators for Heart Disease Sales by Country (2021-2026) & (Units) Table 59. Global Vasodilators for Heart Disease Sales Market Share by Country (2021-2026) Table 60. Global Vasodilators for Heart Disease Sales by Country (2027-2032) & (Units) Table 61. Global Vasodilators for Heart Disease Sales Market Share by Country (2027-2032) Table 62. Global Vasodilators for Heart Disease Sales Value by Country (2021-2026) & (US$ Million) Table 63. Global Vasodilators for Heart Disease Sales Value Market Share by Country (2021-2026) Table 64. Global Vasodilators for Heart Disease Sales Value by Country (2027-2032) & (US$ Million) Table 65. Global Vasodilators for Heart Disease Sales Value Market Share by Country (2027-2032) Table 66. Chongqing Yaoyou Pharmaceutical Co., Ltd. Company Information Table 67. Chongqing Yaoyou Pharmaceutical Co., Ltd. Business Overview Table 68. Chongqing Yaoyou Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Sales (Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 69. Chongqing Yaoyou Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Product Portfolio Table 70. Chongqing Yaoyou Pharmaceutical Co., Ltd. Recent Development Table 71. Southwest Pharmaceutical Co., Ltd. Company Information Table 72. Southwest Pharmaceutical Co., Ltd. Business Overview Table 73. Southwest Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Sales (Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 74. Southwest Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Product Portfolio Table 75. Southwest Pharmaceutical Co., Ltd. Recent Development Table 76. Shanghai Hefeng Pharmaceutical Co., Ltd. Company Information Table 77. Shanghai Hefeng Pharmaceutical Co., Ltd. Business Overview Table 78. Shanghai Hefeng Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Sales (Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 79. Shanghai Hefeng Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Product Portfolio Table 80. Shanghai Hefeng Pharmaceutical Co., Ltd. Recent Development Table 81. Shanghai Aifa Pharmaceutical Co., Ltd. Company Information Table 82. Shanghai Aifa Pharmaceutical Co., Ltd. Business Overview Table 83. Shanghai Aifa Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Sales (Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 84. Shanghai Aifa Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Product Portfolio Table 85. Shanghai Aifa Pharmaceutical Co., Ltd. Recent Development Table 86. Shanxi Kangbao Biological Products Co., Ltd. Company Information Table 87. Shanxi Kangbao Biological Products Co., Ltd. Business Overview Table 88. Shanxi Kangbao Biological Products Co., Ltd. Vasodilators for Heart Disease Sales (Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 89. Shanxi Kangbao Biological Products Co., Ltd. Vasodilators for Heart Disease Product Portfolio Table 90. Shanxi Kangbao Biological Products Co., Ltd. Recent Development Table 91. Shandong New Era Pharmaceutical Co., Ltd. Company Information Table 92. Shandong New Era Pharmaceutical Co., Ltd. Business Overview Table 93. Shandong New Era Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Sales (Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 94. Shandong New Era Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Product Portfolio Table 95. Shandong New Era Pharmaceutical Co., Ltd. Recent Development Table 96. Shandong Fangming Pharmaceutical Group Co., Ltd. Company Information Table 97. Shandong Fangming Pharmaceutical Group Co., Ltd. Business Overview Table 98. Shandong Fangming Pharmaceutical Group Co., Ltd. Vasodilators for Heart Disease Sales (Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 99. Shandong Fangming Pharmaceutical Group Co., Ltd. Vasodilators for Heart Disease Product Portfolio Table 100. Shandong Fangming Pharmaceutical Group Co., Ltd. Recent Development Table 101. Sancai Shiqi Pharmaceutical Co., Ltd. Company Information Table 102. Sancai Shiqi Pharmaceutical Co., Ltd. Business Overview Table 103. Sancai Shiqi Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Sales (Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 104. Sancai Shiqi Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Product Portfolio Table 105. Sancai Shiqi Pharmaceutical Co., Ltd. Recent Development Table 106. Lunan Beite Pharmaceutical Co., Ltd. Company Information Table 107. Lunan Beite Pharmaceutical Co., Ltd. Business Overview Table 108. Lunan Beite Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Sales (Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 109. Lunan Beite Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Product Portfolio Table 110. Lunan Beite Pharmaceutical Co., Ltd. Recent Development Table 111. Jiangxi Haiersi Pharmaceutical Co., Ltd. Company Information Table 112. Jiangxi Haiersi Pharmaceutical Co., Ltd. Business Overview Table 113. Jiangxi Haiersi Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Sales (Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 114. Jiangxi Haiersi Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Product Portfolio Table 115. Jiangxi Haiersi Pharmaceutical Co., Ltd. Recent Development Table 116. Jiangsu Tasly Diyi Pharmaceutical Co., Ltd. Company Information Table 117. Jiangsu Tasly Diyi Pharmaceutical Co., Ltd. Business Overview Table 118. Jiangsu Tasly Diyi Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Sales (Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 119. Jiangsu Tasly Diyi Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Product Portfolio Table 120. Jiangsu Tasly Diyi Pharmaceutical Co., Ltd. Recent Development Table 121. Jiangsu Shenlong Pharmaceutical Co., Ltd. Company Information Table 122. Jiangsu Shenlong Pharmaceutical Co., Ltd. Business Overview Table 123. Jiangsu Shenlong Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Sales (Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 124. Jiangsu Shenlong Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Product Portfolio Table 125. Jiangsu Shenlong Pharmaceutical Co., Ltd. Recent Development Table 126. Jiangsu Jiuxu Pharmaceutical Co., Ltd. Company Information Table 127. Jiangsu Jiuxu Pharmaceutical Co., Ltd. Business Overview Table 128. Jiangsu Jiuxu Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Sales (Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 129. Jiangsu Jiuxu Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Product Portfolio Table 130. Jiangsu Jiuxu Pharmaceutical Co., Ltd. Recent Development Table 131. Huiyinbi Group Jiangxi East Asia Pharmaceutical Co., Ltd. Company Information Table 132. Huiyinbi Group Jiangxi East Asia Pharmaceutical Co., Ltd. Business Overview Table 133. Huiyinbi Group Jiangxi East Asia Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Sales (Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 134. Huiyinbi Group Jiangxi East Asia Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Product Portfolio Table 135. Huiyinbi Group Jiangxi East Asia Pharmaceutical Co., Ltd. Recent Development Table 136. Hulunbeier Songlu Pharmaceutical Co., Ltd. Company Information Table 137. Hulunbeier Songlu Pharmaceutical Co., Ltd. Business Overview Table 138. Hulunbeier Songlu Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Sales (Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 139. Hulunbeier Songlu Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Product Portfolio Table 140. Hulunbeier Songlu Pharmaceutical Co., Ltd. Recent Development Table 141. Henan Runhong Pharmaceutical Co., Ltd. Company Information Table 142. Henan Runhong Pharmaceutical Co., Ltd. Business Overview Table 143. Henan Runhong Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Sales (Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 144. Henan Runhong Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Product Portfolio Table 145. Henan Runhong Pharmaceutical Co., Ltd. Recent Development Table 146. Guangzhou Baiyunshan Mingxing Pharmaceutical Co., Ltd. Company Information Table 147. Guangzhou Baiyunshan Mingxing Pharmaceutical Co., Ltd. Business Overview Table 148. Guangzhou Baiyunshan Mingxing Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Sales (Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 149. Guangzhou Baiyunshan Mingxing Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Product Portfolio Table 150. Guangzhou Baiyunshan Mingxing Pharmaceutical Co., Ltd. Recent Development Table 151. Chenxin Pharmaceutical Co., Ltd. Company Information Table 152. Chenxin Pharmaceutical Co., Ltd. Business Overview Table 153. Chenxin Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Sales (Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 154. Chenxin Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Product Portfolio Table 155. Chenxin Pharmaceutical Co., Ltd. Recent Development Table 156. Beijing Yimin Pharmaceutical Co., Ltd. Company Information Table 157. Beijing Yimin Pharmaceutical Co., Ltd. Business Overview Table 158. Beijing Yimin Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Sales (Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 159. Beijing Yimin Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Product Portfolio Table 160. Beijing Yimin Pharmaceutical Co., Ltd. Recent Development Table 161. Beijing Hengsheng Pharmaceutical Co., Ltd. Company Information Table 162. Beijing Hengsheng Pharmaceutical Co., Ltd. Business Overview Table 163. Beijing Hengsheng Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Sales (Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 164. Beijing Hengsheng Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Product Portfolio Table 165. Beijing Hengsheng Pharmaceutical Co., Ltd. Recent Development Table 166. Anhui Fengyuan Pharmaceutical Co., Ltd. Company Information Table 167. Anhui Fengyuan Pharmaceutical Co., Ltd. Business Overview Table 168. Anhui Fengyuan Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Sales (Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 169. Anhui Fengyuan Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Product Portfolio Table 170. Anhui Fengyuan Pharmaceutical Co., Ltd. Recent Development Table 171. TORRENT PHARMA INC. Company Information Table 172. TORRENT PHARMA INC. Business Overview Table 173. TORRENT PHARMA INC. Vasodilators for Heart Disease Sales (Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 174. TORRENT PHARMA INC. Vasodilators for Heart Disease Product Portfolio Table 175. TORRENT PHARMA INC. Recent Development Table 176. Sanofi Company Information Table 177. Sanofi Business Overview Table 178. Sanofi Vasodilators for Heart Disease Sales (Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 179. Sanofi Vasodilators for Heart Disease Product Portfolio Table 180. Sanofi Recent Development Table 181. Pfizer Company Information Table 182. Pfizer Business Overview Table 183. Pfizer Vasodilators for Heart Disease Sales (Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 184. Pfizer Vasodilators for Heart Disease Product Portfolio Table 185. Pfizer Recent Development Table 186. Matins Pharma Company Information Table 187. Matins Pharma Business Overview Table 188. Matins Pharma Vasodilators for Heart Disease Sales (Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 189. Matins Pharma Vasodilators for Heart Disease Product Portfolio Table 190. Matins Pharma Recent Development Table 191. Copperhead Chemical Company Company Information Table 192. Copperhead Chemical Company Business Overview Table 193. Copperhead Chemical Company Vasodilators for Heart Disease Sales (Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 194. Copperhead Chemical Company Vasodilators for Heart Disease Product Portfolio Table 195. Copperhead Chemical Company Recent Development Table 196. Axplora Company Information Table 197. Axplora Business Overview Table 198. Axplora Vasodilators for Heart Disease Sales (Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 199. Axplora Vasodilators for Heart Disease Product Portfolio Table 200. Axplora Recent Development Table 201. Aditya Chemicals Company Information Table 202. Aditya Chemicals Business Overview Table 203. Aditya Chemicals Vasodilators for Heart Disease Sales (Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 204. Aditya Chemicals Vasodilators for Heart Disease Product Portfolio Table 205. Aditya Chemicals Recent Development Table 206. Key Raw Materials Table 207. Raw Materials Key Suppliers Table 208. Vasodilators for Heart Disease Distributors List Table 209. Vasodilators for Heart Disease Customers List Table 210. Research Programs/Design for This Report Table 211. Authors List of This Report Table 212. Secondary Sources Table 213. Primary Sources List of Figures Figure 1. Vasodilators for Heart Disease Product Image Figure 2. Global Vasodilators for Heart Disease Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Vasodilators for Heart Disease Sales Value (2021-2032) & (US$ Million) Figure 4. Global Vasodilators for Heart Disease Sales (2021-2032) & (Units) Figure 5. Global Vasodilators for Heart Disease Sales Average Price (US$/Unit) & (2021-2032) Figure 6. Global Vasodilators for Heart Disease Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Isosorbide Mononitrate Image Figure 10. Nicorandil Image Figure 11. Nitroglycerin Image Figure 12. Isosorbide Dinitrate Image Figure 13. Global Vasodilators for Heart Disease Sales Volume by Type (2021 VS 2025 VS 2032) & (Units) Figure 14. Global Vasodilators for Heart Disease Sales Volume Share 2021 VS 2025 VS 2032 Figure 15. Global Vasodilators for Heart Disease Sales Volume Share by Type (2021-2032) Figure 16. Global Vasodilators for Heart Disease Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 17. Global Vasodilators for Heart Disease Sales Value Share 2021 VS 2025 VS 2032 Figure 18. Global Vasodilators for Heart Disease Sales Value Share by Type (2021-2032) Figure 19. Clinic Image Figure 20. Hospital Image Figure 21. Other Image Figure 22. Global Vasodilators for Heart Disease Sales Volume by Application (2021 VS 2025 VS 2032) & (Units) Figure 23. Global Vasodilators for Heart Disease Sales Volume Share 2021 VS 2025 VS 2032 Figure 24. Global Vasodilators for Heart Disease Sales Volume Share by Application (2021-2032) Figure 25. Global Vasodilators for Heart Disease Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 26. Global Vasodilators for Heart Disease Sales Value Share 2021 VS 2025 VS 2032 Figure 27. Global Vasodilators for Heart Disease Sales Value Share by Application (2021-2032) Figure 28. Global Vasodilators for Heart Disease Sales by Region: 2021 VS 2025 VS 2032 (Units) Figure 29. Global Vasodilators for Heart Disease Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 30. Global Vasodilators for Heart Disease Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 31. Global Vasodilators for Heart Disease Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 32. North America Vasodilators for Heart Disease Sales Value (2021-2032) & (US$ Million) Figure 33. North America Vasodilators for Heart Disease Sales Value Share by Country (%), 2025 VS 2032 Figure 34. Europe Vasodilators for Heart Disease Sales Value (2021-2032) & (US$ Million) Figure 35. Europe Vasodilators for Heart Disease Sales Value Share by Country (%), 2025 VS 2032 Figure 36. Asia-Pacific Vasodilators for Heart Disease Sales Value (2021-2032) & (US$ Million) Figure 37. Asia-Pacific Vasodilators for Heart Disease Sales Value Share by Country (%), 2025 VS 2032 Figure 38. South America Vasodilators for Heart Disease Sales Value (2021-2032) & (US$ Million) Figure 39. South America Vasodilators for Heart Disease Sales Value Share by Country (%), 2025 VS 2032 Figure 40. Middle East & Africa Vasodilators for Heart Disease Sales Value (2021-2032) & (US$ Million) Figure 41. Middle East & Africa Vasodilators for Heart Disease Sales Value Share by Country (%), 2025 VS 2032 Figure 42. USA Vasodilators for Heart Disease Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. USA Vasodilators for Heart Disease Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. USA Vasodilators for Heart Disease Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. Canada Vasodilators for Heart Disease Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. Canada Vasodilators for Heart Disease Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. Canada Vasodilators for Heart Disease Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. Mexico Vasodilators for Heart Disease Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. Mexico Vasodilators for Heart Disease Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. Mexico Vasodilators for Heart Disease Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. Germany Vasodilators for Heart Disease Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. Germany Vasodilators for Heart Disease Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. Germany Vasodilators for Heart Disease Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. France Vasodilators for Heart Disease Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. France Vasodilators for Heart Disease Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. France Vasodilators for Heart Disease Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. U.K. Vasodilators for Heart Disease Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. U.K. Vasodilators for Heart Disease Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. U.K. Vasodilators for Heart Disease Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Italy Vasodilators for Heart Disease Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Italy Vasodilators for Heart Disease Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Italy Vasodilators for Heart Disease Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. Spain Vasodilators for Heart Disease Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. Spain Vasodilators for Heart Disease Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. Spain Vasodilators for Heart Disease Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Russia Vasodilators for Heart Disease Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Russia Vasodilators for Heart Disease Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Russia Vasodilators for Heart Disease Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. Netherlands Vasodilators for Heart Disease Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. Netherlands Vasodilators for Heart Disease Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. Netherlands Vasodilators for Heart Disease Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. Nordic Countries Vasodilators for Heart Disease Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. Nordic Countries Vasodilators for Heart Disease Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. Nordic Countries Vasodilators for Heart Disease Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. China Vasodilators for Heart Disease Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. China Vasodilators for Heart Disease Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. China Vasodilators for Heart Disease Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. Japan Vasodilators for Heart Disease Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. Japan Vasodilators for Heart Disease Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. Japan Vasodilators for Heart Disease Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. South Korea Vasodilators for Heart Disease Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. South Korea Vasodilators for Heart Disease Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. South Korea Vasodilators for Heart Disease Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. India Vasodilators for Heart Disease Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. India Vasodilators for Heart Disease Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. India Vasodilators for Heart Disease Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Australia Vasodilators for Heart Disease Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Australia Vasodilators for Heart Disease Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Australia Vasodilators for Heart Disease Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Southeast Asia Vasodilators for Heart Disease Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Southeast Asia Vasodilators for Heart Disease Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Southeast Asia Vasodilators for Heart Disease Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Brazil Vasodilators for Heart Disease Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Brazil Vasodilators for Heart Disease Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Brazil Vasodilators for Heart Disease Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Argentina Vasodilators for Heart Disease Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Argentina Vasodilators for Heart Disease Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Argentina Vasodilators for Heart Disease Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Chile Vasodilators for Heart Disease Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Chile Vasodilators for Heart Disease Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Chile Vasodilators for Heart Disease Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. Colombia Vasodilators for Heart Disease Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. Colombia Vasodilators for Heart Disease Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. Colombia Vasodilators for Heart Disease Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Peru Vasodilators for Heart Disease Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Peru Vasodilators for Heart Disease Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Peru Vasodilators for Heart Disease Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Saudi Arabia Vasodilators for Heart Disease Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Saudi Arabia Vasodilators for Heart Disease Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Saudi Arabia Vasodilators for Heart Disease Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. Israel Vasodilators for Heart Disease Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. Israel Arabia Vasodilators for Heart Disease Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. Israel Arabia Vasodilators for Heart Disease Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. UAE Vasodilators for Heart Disease Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 115. UAE Vasodilators for Heart Disease Sales Value Share by Type, 2025 VS 2032 & (%) Figure 116. UAE Vasodilators for Heart Disease Sales Value Share by Application, 2025 VS 2032 & (%) Figure 117. Turkey Vasodilators for Heart Disease Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 118. Turkey Vasodilators for Heart Disease Sales Value Share by Type, 2025 VS 2032 & (%) Figure 119. Turkey Vasodilators for Heart Disease Sales Value Share by Application, 2025 VS 2032 & (%) Figure 120. Iran Vasodilators for Heart Disease Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 121. Iran Vasodilators for Heart Disease Sales Value Share by Type, 2025 VS 2032 & (%) Figure 122. Iran Vasodilators for Heart Disease Sales Value Share by Application, 2025 VS 2032 & (%) Figure 123. Egypt Vasodilators for Heart Disease Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 124. Egypt Vasodilators for Heart Disease Sales Value Share by Type, 2025 VS 2032 & (%) Figure 125. Egypt Vasodilators for Heart Disease Sales Value Share by Application, 2025 VS 2032 & (%) Figure 126. Vasodilators for Heart Disease Value Chain Figure 127. Manufacturing Cost Structure Figure 128. Vasodilators for Heart Disease Sales Mode & Process Figure 129. Direct Comparison with Distribution Share Figure 130. Distributors Profiles Figure 131. Years Considered Figure 132. Research Process Figure 133. Key Executives Interviewed

Scope & coverage.

Types
  • Isosorbide Mononitrate
  • Nicorandil
  • Nitroglycerin
  • Isosorbide Dinitrate
Applications
  • Clinic
  • Hospital
  • Other
Companies covered
  • Chongqing Yaoyou Pharmaceutical Co., Ltd.
  • Southwest Pharmaceutical Co., Ltd.
  • Shanghai Hefeng Pharmaceutical Co., Ltd.
  • Shanghai Aifa Pharmaceutical Co., Ltd.
  • Shanxi Kangbao Biological Products Co., Ltd.
  • Shandong New Era Pharmaceutical Co., Ltd.
  • Shandong Fangming Pharmaceutical Group Co., Ltd.
  • Sancai Shiqi Pharmaceutical Co., Ltd.
  • Lunan Beite Pharmaceutical Co., Ltd.
  • Jiangxi Haiersi Pharmaceutical Co., Ltd.
  • Jiangsu Tasly Diyi Pharmaceutical Co., Ltd.
  • Jiangsu Shenlong Pharmaceutical Co., Ltd.
  • Jiangsu Jiuxu Pharmaceutical Co., Ltd.
  • Huiyinbi Group Jiangxi East Asia Pharmaceutical Co., Ltd.
  • Hulunbeier Songlu Pharmaceutical Co., Ltd.
  • Henan Runhong Pharmaceutical Co., Ltd.
  • Guangzhou Baiyunshan Mingxing Pharmaceutical Co., Ltd.
  • Chenxin Pharmaceutical Co., Ltd.
  • Beijing Yimin Pharmaceutical Co., Ltd.
  • Beijing Hengsheng Pharmaceutical Co., Ltd.
  • Anhui Fengyuan Pharmaceutical Co., Ltd.
  • TORRENT PHARMA INC.
  • Sanofi
  • Pfizer
  • Matins Pharma
  • Copperhead Chemical Company
  • Axplora
  • Aditya Chemicals

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Vasodilators for Heart Disease Sales Value (2021-2032)
  4. 1.2.2 Global Vasodilators for Heart Disease Sales Volume (2021-2032)
  5. 1.2.3 Global Vasodilators for Heart Disease Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Vasodilators for Heart Disease Market Dynamics
  1. 2.1 Vasodilators for Heart Disease Industry Trends
  2. 2.2 Vasodilators for Heart Disease Industry Drivers
  3. 2.3 Vasodilators for Heart Disease Industry Opportunities and Challenges
  4. 2.4 Vasodilators for Heart Disease Industry Restraints
3 Vasodilators for Heart Disease Market by Company
  1. 3.1 Global Vasodilators for Heart Disease Company Revenue Ranking in 2025
  2. 3.2 Global Vasodilators for Heart Disease Revenue by Company (2021-2026)
  3. 3.3 Global Vasodilators for Heart Disease Sales Volume by Company (2021-2026)
  4. 3.4 Global Vasodilators for Heart Disease Average Price by Company (2021-2026)
  5. 3.5 Global Vasodilators for Heart Disease Company Ranking (2024-2026)
  6. 3.6 Global Vasodilators for Heart Disease Company Manufacturing Base and Headquarters
  7. 3.7 Global Vasodilators for Heart Disease Company Product Type and Application
  8. 3.8 Global Vasodilators for Heart Disease Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Vasodilators for Heart Disease Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Vasodilators for Heart Disease Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Vasodilators for Heart Disease Market by Type
  1. 4.1 Vasodilators for Heart Disease Type Introduction
  2. 4.1.1 Isosorbide Mononitrate
  3. 4.1.2 Nicorandil
  4. 4.1.3 Nitroglycerin
  5. 4.1.4 Isosorbide Dinitrate
  6. 4.2 Global Vasodilators for Heart Disease Sales Volume by Type
  7. 4.2.1 Global Vasodilators for Heart Disease Sales Volume by Type (2021 VS 2025 VS 2032)
  8. 4.2.2 Global Vasodilators for Heart Disease Sales Volume by Type (2021-2032)
  9. 4.2.3 Global Vasodilators for Heart Disease Sales Volume Share by Type (2021-2032)
  10. 4.3 Global Vasodilators for Heart Disease Sales Value by Type
  11. 4.3.1 Global Vasodilators for Heart Disease Sales Value by Type (2021 VS 2025 VS 2032)
  12. 4.3.2 Global Vasodilators for Heart Disease Sales Value by Type (2021-2032)
  13. 4.3.3 Global Vasodilators for Heart Disease Sales Value Share by Type (2021-2032)
5 Vasodilators for Heart Disease Market by Application
  1. 5.1 Vasodilators for Heart Disease Application Introduction
  2. 5.1.1 Clinic
  3. 5.1.2 Hospital
  4. 5.1.3 Other
  5. 5.2 Global Vasodilators for Heart Disease Sales Volume by Application
  6. 5.2.1 Global Vasodilators for Heart Disease Sales Volume by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Vasodilators for Heart Disease Sales Volume by Application (2021-2032)
  8. 5.2.3 Global Vasodilators for Heart Disease Sales Volume Share by Application (2021-2032)
  9. 5.3 Global Vasodilators for Heart Disease Sales Value by Application
  10. 5.3.1 Global Vasodilators for Heart Disease Sales Value by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Vasodilators for Heart Disease Sales Value by Application (2021-2032)
  12. 5.3.3 Global Vasodilators for Heart Disease Sales Value Share by Application (2021-2032)
6 Vasodilators for Heart Disease Regional Sales and Value Analysis
  1. 6.1 Global Vasodilators for Heart Disease Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Vasodilators for Heart Disease Sales by Region (2021-2032)
  3. 6.2.1 Global Vasodilators for Heart Disease Sales by Region: 2021-2026
  4. 6.2.2 Global Vasodilators for Heart Disease Sales by Region (2027-2032)
  5. 6.3 Global Vasodilators for Heart Disease Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Vasodilators for Heart Disease Sales Value by Region (2021-2032)
  7. 6.4.1 Global Vasodilators for Heart Disease Sales Value by Region: 2021-2026
  8. 6.4.2 Global Vasodilators for Heart Disease Sales Value by Region (2027-2032)
  9. 6.5 Global Vasodilators for Heart Disease Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Vasodilators for Heart Disease Sales Value (2021-2032)
  12. 6.6.2 North America Vasodilators for Heart Disease Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Vasodilators for Heart Disease Sales Value (2021-2032)
  15. 6.7.2 Europe Vasodilators for Heart Disease Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Vasodilators for Heart Disease Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Vasodilators for Heart Disease Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Vasodilators for Heart Disease Sales Value (2021-2032)
  21. 6.9.2 South America Vasodilators for Heart Disease Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Vasodilators for Heart Disease Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Vasodilators for Heart Disease Sales Value Share by Country, 2025 VS 2032
7 Vasodilators for Heart Disease Country-level Sales and Value Analysis
  1. 7.1 Global Vasodilators for Heart Disease Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Vasodilators for Heart Disease Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Vasodilators for Heart Disease Sales by Country (2021-2032)
  4. 7.3.1 Global Vasodilators for Heart Disease Sales by Country (2021-2026)
  5. 7.3.2 Global Vasodilators for Heart Disease Sales by Country (2027-2032)
  6. 7.4 Global Vasodilators for Heart Disease Sales Value by Country (2021-2032)
  7. 7.4.1 Global Vasodilators for Heart Disease Sales Value by Country (2021-2026)
  8. 7.4.2 Global Vasodilators for Heart Disease Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Vasodilators for Heart Disease Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Vasodilators for Heart Disease Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Vasodilators for Heart Disease Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Vasodilators for Heart Disease Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Vasodilators for Heart Disease Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Vasodilators for Heart Disease Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Vasodilators for Heart Disease Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Vasodilators for Heart Disease Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Vasodilators for Heart Disease Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Vasodilators for Heart Disease Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Vasodilators for Heart Disease Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Vasodilators for Heart Disease Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Vasodilators for Heart Disease Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Vasodilators for Heart Disease Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Vasodilators for Heart Disease Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Vasodilators for Heart Disease Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Vasodilators for Heart Disease Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Vasodilators for Heart Disease Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Vasodilators for Heart Disease Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Vasodilators for Heart Disease Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Vasodilators for Heart Disease Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Vasodilators for Heart Disease Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Vasodilators for Heart Disease Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Vasodilators for Heart Disease Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Vasodilators for Heart Disease Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Vasodilators for Heart Disease Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Vasodilators for Heart Disease Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Vasodilators for Heart Disease Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Vasodilators for Heart Disease Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Vasodilators for Heart Disease Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Vasodilators for Heart Disease Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Vasodilators for Heart Disease Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Vasodilators for Heart Disease Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Vasodilators for Heart Disease Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Vasodilators for Heart Disease Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Vasodilators for Heart Disease Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Vasodilators for Heart Disease Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Vasodilators for Heart Disease Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Vasodilators for Heart Disease Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Vasodilators for Heart Disease Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Vasodilators for Heart Disease Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Vasodilators for Heart Disease Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Vasodilators for Heart Disease Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Vasodilators for Heart Disease Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Vasodilators for Heart Disease Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Vasodilators for Heart Disease Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Vasodilators for Heart Disease Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Vasodilators for Heart Disease Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Vasodilators for Heart Disease Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Vasodilators for Heart Disease Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Vasodilators for Heart Disease Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Vasodilators for Heart Disease Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Vasodilators for Heart Disease Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Vasodilators for Heart Disease Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Vasodilators for Heart Disease Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Vasodilators for Heart Disease Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Vasodilators for Heart Disease Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Vasodilators for Heart Disease Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Vasodilators for Heart Disease Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Vasodilators for Heart Disease Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Vasodilators for Heart Disease Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Vasodilators for Heart Disease Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Vasodilators for Heart Disease Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Vasodilators for Heart Disease Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Vasodilators for Heart Disease Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Vasodilators for Heart Disease Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Vasodilators for Heart Disease Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Vasodilators for Heart Disease Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Vasodilators for Heart Disease Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Vasodilators for Heart Disease Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Vasodilators for Heart Disease Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Vasodilators for Heart Disease Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Vasodilators for Heart Disease Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Vasodilators for Heart Disease Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Vasodilators for Heart Disease Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Vasodilators for Heart Disease Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Vasodilators for Heart Disease Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Vasodilators for Heart Disease Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Vasodilators for Heart Disease Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Vasodilators for Heart Disease Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Vasodilators for Heart Disease Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Vasodilators for Heart Disease Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Vasodilators for Heart Disease Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Vasodilators for Heart Disease Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Chongqing Yaoyou Pharmaceutical Co., Ltd.
  2. 8.1.1 Chongqing Yaoyou Pharmaceutical Co., Ltd. Company Information
  3. 8.1.2 Chongqing Yaoyou Pharmaceutical Co., Ltd. Business Overview
  4. 8.1.3 Chongqing Yaoyou Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Chongqing Yaoyou Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Product Portfolio
  6. 8.1.5 Chongqing Yaoyou Pharmaceutical Co., Ltd. Recent Developments
  7. 8.2 Southwest Pharmaceutical Co., Ltd.
  8. 8.2.1 Southwest Pharmaceutical Co., Ltd. Company Information
  9. 8.2.2 Southwest Pharmaceutical Co., Ltd. Business Overview
  10. 8.2.3 Southwest Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Southwest Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Product Portfolio
  12. 8.2.5 Southwest Pharmaceutical Co., Ltd. Recent Developments
  13. 8.3 Shanghai Hefeng Pharmaceutical Co., Ltd.
  14. 8.3.1 Shanghai Hefeng Pharmaceutical Co., Ltd. Company Information
  15. 8.3.2 Shanghai Hefeng Pharmaceutical Co., Ltd. Business Overview
  16. 8.3.3 Shanghai Hefeng Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Shanghai Hefeng Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Product Portfolio
  18. 8.3.5 Shanghai Hefeng Pharmaceutical Co., Ltd. Recent Developments
  19. 8.4 Shanghai Aifa Pharmaceutical Co., Ltd.
  20. 8.4.1 Shanghai Aifa Pharmaceutical Co., Ltd. Company Information
  21. 8.4.2 Shanghai Aifa Pharmaceutical Co., Ltd. Business Overview
  22. 8.4.3 Shanghai Aifa Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Shanghai Aifa Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Product Portfolio
  24. 8.4.5 Shanghai Aifa Pharmaceutical Co., Ltd. Recent Developments
  25. 8.5 Shanxi Kangbao Biological Products Co., Ltd.
  26. 8.5.1 Shanxi Kangbao Biological Products Co., Ltd. Company Information
  27. 8.5.2 Shanxi Kangbao Biological Products Co., Ltd. Business Overview
  28. 8.5.3 Shanxi Kangbao Biological Products Co., Ltd. Vasodilators for Heart Disease Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Shanxi Kangbao Biological Products Co., Ltd. Vasodilators for Heart Disease Product Portfolio
  30. 8.5.5 Shanxi Kangbao Biological Products Co., Ltd. Recent Developments
  31. 8.6 Shandong New Era Pharmaceutical Co., Ltd.
  32. 8.6.1 Shandong New Era Pharmaceutical Co., Ltd. Company Information
  33. 8.6.2 Shandong New Era Pharmaceutical Co., Ltd. Business Overview
  34. 8.6.3 Shandong New Era Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Shandong New Era Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Product Portfolio
  36. 8.6.5 Shandong New Era Pharmaceutical Co., Ltd. Recent Developments
  37. 8.7 Shandong Fangming Pharmaceutical Group Co., Ltd.
  38. 8.7.1 Shandong Fangming Pharmaceutical Group Co., Ltd. Company Information
  39. 8.7.2 Shandong Fangming Pharmaceutical Group Co., Ltd. Business Overview
  40. 8.7.3 Shandong Fangming Pharmaceutical Group Co., Ltd. Vasodilators for Heart Disease Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Shandong Fangming Pharmaceutical Group Co., Ltd. Vasodilators for Heart Disease Product Portfolio
  42. 8.7.5 Shandong Fangming Pharmaceutical Group Co., Ltd. Recent Developments
  43. 8.8 Sancai Shiqi Pharmaceutical Co., Ltd.
  44. 8.8.1 Sancai Shiqi Pharmaceutical Co., Ltd. Company Information
  45. 8.8.2 Sancai Shiqi Pharmaceutical Co., Ltd. Business Overview
  46. 8.8.3 Sancai Shiqi Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Sancai Shiqi Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Product Portfolio
  48. 8.8.5 Sancai Shiqi Pharmaceutical Co., Ltd. Recent Developments
  49. 8.9 Lunan Beite Pharmaceutical Co., Ltd.
  50. 8.9.1 Lunan Beite Pharmaceutical Co., Ltd. Company Information
  51. 8.9.2 Lunan Beite Pharmaceutical Co., Ltd. Business Overview
  52. 8.9.3 Lunan Beite Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 Lunan Beite Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Product Portfolio
  54. 8.9.5 Lunan Beite Pharmaceutical Co., Ltd. Recent Developments
  55. 8.10 Jiangxi Haiersi Pharmaceutical Co., Ltd.
  56. 8.10.1 Jiangxi Haiersi Pharmaceutical Co., Ltd. Company Information
  57. 8.10.2 Jiangxi Haiersi Pharmaceutical Co., Ltd. Business Overview
  58. 8.10.3 Jiangxi Haiersi Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 Jiangxi Haiersi Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Product Portfolio
  60. 8.10.5 Jiangxi Haiersi Pharmaceutical Co., Ltd. Recent Developments
  61. 8.11 Jiangsu Tasly Diyi Pharmaceutical Co., Ltd.
  62. 8.11.1 Jiangsu Tasly Diyi Pharmaceutical Co., Ltd. Company Information
  63. 8.11.2 Jiangsu Tasly Diyi Pharmaceutical Co., Ltd. Business Overview
  64. 8.11.3 Jiangsu Tasly Diyi Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Sales, Value and Gross Margin (2021-2026)
  65. 8.11.4 Jiangsu Tasly Diyi Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Product Portfolio
  66. 8.11.5 Jiangsu Tasly Diyi Pharmaceutical Co., Ltd. Recent Developments
  67. 8.12 Jiangsu Shenlong Pharmaceutical Co., Ltd.
  68. 8.12.1 Jiangsu Shenlong Pharmaceutical Co., Ltd. Company Information
  69. 8.12.2 Jiangsu Shenlong Pharmaceutical Co., Ltd. Business Overview
  70. 8.12.3 Jiangsu Shenlong Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Sales, Value and Gross Margin (2021-2026)
  71. 8.12.4 Jiangsu Shenlong Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Product Portfolio
  72. 8.12.5 Jiangsu Shenlong Pharmaceutical Co., Ltd. Recent Developments
  73. 8.13 Jiangsu Jiuxu Pharmaceutical Co., Ltd.
  74. 8.13.1 Jiangsu Jiuxu Pharmaceutical Co., Ltd. Company Information
  75. 8.13.2 Jiangsu Jiuxu Pharmaceutical Co., Ltd. Business Overview
  76. 8.13.3 Jiangsu Jiuxu Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Sales, Value and Gross Margin (2021-2026)
  77. 8.13.4 Jiangsu Jiuxu Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Product Portfolio
  78. 8.13.5 Jiangsu Jiuxu Pharmaceutical Co., Ltd. Recent Developments
  79. 8.14 Huiyinbi Group Jiangxi East Asia Pharmaceutical Co., Ltd.
  80. 8.14.1 Huiyinbi Group Jiangxi East Asia Pharmaceutical Co., Ltd. Company Information
  81. 8.14.2 Huiyinbi Group Jiangxi East Asia Pharmaceutical Co., Ltd. Business Overview
  82. 8.14.3 Huiyinbi Group Jiangxi East Asia Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Sales, Value and Gross Margin (2021-2026)
  83. 8.14.4 Huiyinbi Group Jiangxi East Asia Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Product Portfolio
  84. 8.14.5 Huiyinbi Group Jiangxi East Asia Pharmaceutical Co., Ltd. Recent Developments
  85. 8.15 Hulunbeier Songlu Pharmaceutical Co., Ltd.
  86. 8.15.1 Hulunbeier Songlu Pharmaceutical Co., Ltd. Company Information
  87. 8.15.2 Hulunbeier Songlu Pharmaceutical Co., Ltd. Business Overview
  88. 8.15.3 Hulunbeier Songlu Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Sales, Value and Gross Margin (2021-2026)
  89. 8.15.4 Hulunbeier Songlu Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Product Portfolio
  90. 8.15.5 Hulunbeier Songlu Pharmaceutical Co., Ltd. Recent Developments
  91. 8.16 Henan Runhong Pharmaceutical Co., Ltd.
  92. 8.16.1 Henan Runhong Pharmaceutical Co., Ltd. Company Information
  93. 8.16.2 Henan Runhong Pharmaceutical Co., Ltd. Business Overview
  94. 8.16.3 Henan Runhong Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Sales, Value and Gross Margin (2021-2026)
  95. 8.16.4 Henan Runhong Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Product Portfolio
  96. 8.16.5 Henan Runhong Pharmaceutical Co., Ltd. Recent Developments
  97. 8.17 Guangzhou Baiyunshan Mingxing Pharmaceutical Co., Ltd.
  98. 8.17.1 Guangzhou Baiyunshan Mingxing Pharmaceutical Co., Ltd. Company Information
  99. 8.17.2 Guangzhou Baiyunshan Mingxing Pharmaceutical Co., Ltd. Business Overview
  100. 8.17.3 Guangzhou Baiyunshan Mingxing Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Sales, Value and Gross Margin (2021-2026)
  101. 8.17.4 Guangzhou Baiyunshan Mingxing Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Product Portfolio
  102. 8.17.5 Guangzhou Baiyunshan Mingxing Pharmaceutical Co., Ltd. Recent Developments
  103. 8.18 Chenxin Pharmaceutical Co., Ltd.
  104. 8.18.1 Chenxin Pharmaceutical Co., Ltd. Company Information
  105. 8.18.2 Chenxin Pharmaceutical Co., Ltd. Business Overview
  106. 8.18.3 Chenxin Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Sales, Value and Gross Margin (2021-2026)
  107. 8.18.4 Chenxin Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Product Portfolio
  108. 8.18.5 Chenxin Pharmaceutical Co., Ltd. Recent Developments
  109. 8.19 Beijing Yimin Pharmaceutical Co., Ltd.
  110. 8.19.1 Beijing Yimin Pharmaceutical Co., Ltd. Company Information
  111. 8.19.2 Beijing Yimin Pharmaceutical Co., Ltd. Business Overview
  112. 8.19.3 Beijing Yimin Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Sales, Value and Gross Margin (2021-2026)
  113. 8.19.4 Beijing Yimin Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Product Portfolio
  114. 8.19.5 Beijing Yimin Pharmaceutical Co., Ltd. Recent Developments
  115. 8.20 Beijing Hengsheng Pharmaceutical Co., Ltd.
  116. 8.20.1 Beijing Hengsheng Pharmaceutical Co., Ltd. Company Information
  117. 8.20.2 Beijing Hengsheng Pharmaceutical Co., Ltd. Business Overview
  118. 8.20.3 Beijing Hengsheng Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Sales, Value and Gross Margin (2021-2026)
  119. 8.20.4 Beijing Hengsheng Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Product Portfolio
  120. 8.20.5 Beijing Hengsheng Pharmaceutical Co., Ltd. Recent Developments
  121. 8.21 Anhui Fengyuan Pharmaceutical Co., Ltd.
  122. 8.21.1 Anhui Fengyuan Pharmaceutical Co., Ltd. Company Information
  123. 8.21.2 Anhui Fengyuan Pharmaceutical Co., Ltd. Business Overview
  124. 8.21.3 Anhui Fengyuan Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Sales, Value and Gross Margin (2021-2026)
  125. 8.21.4 Anhui Fengyuan Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Product Portfolio
  126. 8.21.5 Anhui Fengyuan Pharmaceutical Co., Ltd. Recent Developments
  127. 8.22 TORRENT PHARMA INC.
  128. 8.22.1 TORRENT PHARMA INC. Company Information
  129. 8.22.2 TORRENT PHARMA INC. Business Overview
  130. 8.22.3 TORRENT PHARMA INC. Vasodilators for Heart Disease Sales, Value and Gross Margin (2021-2026)
  131. 8.22.4 TORRENT PHARMA INC. Vasodilators for Heart Disease Product Portfolio
  132. 8.22.5 TORRENT PHARMA INC. Recent Developments
  133. 8.23 Sanofi
  134. 8.23.1 Sanofi Company Information
  135. 8.23.2 Sanofi Business Overview
  136. 8.23.3 Sanofi Vasodilators for Heart Disease Sales, Value and Gross Margin (2021-2026)
  137. 8.23.4 Sanofi Vasodilators for Heart Disease Product Portfolio
  138. 8.23.5 Sanofi Recent Developments
  139. 8.24 Pfizer
  140. 8.24.1 Pfizer Company Information
  141. 8.24.2 Pfizer Business Overview
  142. 8.24.3 Pfizer Vasodilators for Heart Disease Sales, Value and Gross Margin (2021-2026)
  143. 8.24.4 Pfizer Vasodilators for Heart Disease Product Portfolio
  144. 8.24.5 Pfizer Recent Developments
  145. 8.25 Matins Pharma
  146. 8.25.1 Matins Pharma Company Information
  147. 8.25.2 Matins Pharma Business Overview
  148. 8.25.3 Matins Pharma Vasodilators for Heart Disease Sales, Value and Gross Margin (2021-2026)
  149. 8.25.4 Matins Pharma Vasodilators for Heart Disease Product Portfolio
  150. 8.25.5 Matins Pharma Recent Developments
  151. 8.26 Copperhead Chemical Company
  152. 8.26.1 Copperhead Chemical Company Company Information
  153. 8.26.2 Copperhead Chemical Company Business Overview
  154. 8.26.3 Copperhead Chemical Company Vasodilators for Heart Disease Sales, Value and Gross Margin (2021-2026)
  155. 8.26.4 Copperhead Chemical Company Vasodilators for Heart Disease Product Portfolio
  156. 8.26.5 Copperhead Chemical Company Recent Developments
  157. 8.27 Axplora
  158. 8.27.1 Axplora Company Information
  159. 8.27.2 Axplora Business Overview
  160. 8.27.3 Axplora Vasodilators for Heart Disease Sales, Value and Gross Margin (2021-2026)
  161. 8.27.4 Axplora Vasodilators for Heart Disease Product Portfolio
  162. 8.27.5 Axplora Recent Developments
  163. 8.28 Aditya Chemicals
  164. 8.28.1 Aditya Chemicals Company Information
  165. 8.28.2 Aditya Chemicals Business Overview
  166. 8.28.3 Aditya Chemicals Vasodilators for Heart Disease Sales, Value and Gross Margin (2021-2026)
  167. 8.28.4 Aditya Chemicals Vasodilators for Heart Disease Product Portfolio
  168. 8.28.5 Aditya Chemicals Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Vasodilators for Heart Disease Value Chain Analysis
  2. 9.1.1 Vasodilators for Heart Disease Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Vasodilators for Heart Disease Sales Mode & Process
  6. 9.2 Vasodilators for Heart Disease Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Vasodilators for Heart Disease Distributors
  9. 9.2.3 Vasodilators for Heart Disease Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst